Log In
BCIQ
Print this Print this
 

E6201

  Manage Alerts
Collapse Summary General Information
Company Eisai Co. Ltd.
DescriptionDual FMS-like tyrosine kinase 3 (FLT3; CD135) and MEK inhibitor
Molecular Target MAP kinase kinase 1 (MAP2K1) (MEK1) ; FMS-like tyrosine kinase 3 (FLT3) (CD135)
Mechanism of ActionFMS-like tyrosine kinase 3 (FLT3) inhibitor; MEK inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationAcute myelogenous leukemia (AML)
Indication DetailsTreat acute myelogenous leukemia (AML)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

3

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today